182 related articles for article (PubMed ID: 31641225)
1. Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2.
Lopes N; Bergsland CH; Bjørnslett M; Pellinen T; Svindland A; Nesbakken A; Almeida R; Lothe RA; David L; Bruun J
Lab Invest; 2020 Jan; 100(1):120-134. PubMed ID: 31641225
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
3. A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis.
Lopes N; Bergsland C; Bruun J; Bjørnslett M; Vieira AF; Mesquita P; Pinto R; Gomes R; Cavadas B; Bennett E; Pereira L; Lothe RA; Almeida R; David L
Gastric Cancer; 2020 Sep; 23(5):811-823. PubMed ID: 32215766
[TBL] [Abstract][Full Text] [Related]
4. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome.
Camilo V; Barros R; Celestino R; Castro P; Vieira J; Teixeira MR; Carneiro F; Pinto-de-Sousa J; David L; Almeida R
BMC Cancer; 2014 Oct; 14():753. PubMed ID: 25300947
[TBL] [Abstract][Full Text] [Related]
6. Visible- and near-infrared hyperspectral imaging for the quantitative analysis of PD-L1+ cells in human lymphomas: Comparison with fluorescent multiplex immunohistochemistry.
Brunner A; Willenbacher E; Willenbacher W; Zelger B; Zelger P; Huck CW; Pallua JD
Spectrochim Acta A Mol Biomol Spectrosc; 2023 Jan; 285():121940. PubMed ID: 36208576
[TBL] [Abstract][Full Text] [Related]
7. The Diagnostic Value of Cadherin 17 and CDX2 Expression as Immunohistochemical Markers in Colorectal Adenocarcinoma.
Abouelkhair MB; Mabrouk SH; Zaki SSA; Nada OH; Hakim SA
J Gastrointest Cancer; 2021 Sep; 52(3):960-969. PubMed ID: 32929682
[TBL] [Abstract][Full Text] [Related]
8. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.
Lugli A; Tzankov A; Zlobec I; Terracciano LM
Mod Pathol; 2008 Nov; 21(11):1403-12. PubMed ID: 18587323
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of SOX2 and CDX2 Expression in Barrett's Mucosa.
Barros R; Pereira D; Callé C; Camilo V; Cunha AI; David L; Almeida R; Dias-Pereira A; Chaves P
Dis Markers; 2016; 2016():1532791. PubMed ID: 27766003
[TBL] [Abstract][Full Text] [Related]
11. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
12. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
[TBL] [Abstract][Full Text] [Related]
13. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
Graule J; Uth K; Fischer E; Centeno I; Galván JA; Eichmann M; Rau TT; Langer R; Dawson H; Nitsche U; Traeger P; Berger MD; Schnüriger B; Hädrich M; Studer P; Inderbitzin D; Lugli A; Tschan MP; Zlobec I
Clin Epigenetics; 2018 Sep; 10(1):120. PubMed ID: 30257705
[TBL] [Abstract][Full Text] [Related]
14. CDX2 as a Predictive Biomarker Involved in Immunotherapy Response Suppresses Metastasis through EMT in Colorectal Cancer.
Wang YS; Kou Y; Zhu RT; Han BW; Li CH; Wang HJ; Wu HB; Xia TM; Che XM
Dis Markers; 2022; 2022():9025668. PubMed ID: 36277982
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma.
Altintas S; Bayrak M; Altintas Y
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1057-1061. PubMed ID: 31659962
[TBL] [Abstract][Full Text] [Related]
16. [Expression of Cdx2 protein in colorectal cancer].
Pack JH; Kim TD; Oh HA; Lee EJ; Kim JW; Jang BI; Kim TN; Jung MK; Bae YK
Korean J Gastroenterol; 2005 Sep; 46(3):204-10. PubMed ID: 16179840
[TBL] [Abstract][Full Text] [Related]
17. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
[TBL] [Abstract][Full Text] [Related]
18. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
19. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.
Slik K; Blom S; Turkki R; Välimäki K; Kurki S; Mustonen H; Haglund C; Carpén O; Kallioniemi O; Korkeila E; Sundström J; Pellinen T
J Pathol Clin Res; 2019 Jan; 5(1):63-78. PubMed ID: 30358171
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of CDX2 in colorectal cancers.
Choi BJ; Kim CJ; Cho YG; Song JH; Kim SY; Nam SW; Lee SH; Yoo NJ; Lee JY; Park WS
APMIS; 2006 Jan; 114(1):50-4. PubMed ID: 16499661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
